Jean Liu - Seagen President
| SGENDelisted Stock | USD 228.74 0.19 0.08% |
President
Ms. Jean I. Liu, J.D. is Executive Vice President Legal Affairs, General Counsel, Corporationrationrate Secretary of Seattle Genetics, Inc., since November 2014. Prior to that, she served as Vice President and General Counsel of Halozyme Therapeutics, Inc., a publiclytraded biotechnology company, from November 2011 to November 2014. From 1998 to 2011, she was with Durect Corporationrationration, a publiclytraded biotechnology company, where she served in positions of increasing responsibility, including most recently Chief Legal Officer and Corporationrationrate Secretary. Prior to Durect, Ms. Liu was with the law firms of Pillsbury, Madison Sutro and Venture Law Group where she focused on broad areas of legal advisory for early stage companies, including technology transfer, licensing, patents, and copyright and trademark litigation since 2014.
| Age | 49 |
| Tenure | 10 years |
| Phone | 425 527 4000 |
| Web | https://www.seagen.com |
Seagen Management Efficiency
The company has return on total asset (ROA) of (0.1294) % which means that it has lost $0.1294 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2793) %, meaning that it created substantial loss on money invested by shareholders. Seagen's management efficiency ratios could be used to measure how well Seagen manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 43.47 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Seagen Inc has a current ratio of 4.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Seagen until it has trouble settling it off, either with new capital or with free cash flow. So, Seagen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Seagen Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Seagen to invest in growth at high rates of return. When we think about Seagen's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Daniel Spiegelman | Biomarin Pharmaceutical | 58 | |
| Gregory Zante | Viking Therapeutics | 53 | |
| Kelley Boucher | Alnylam Pharmaceuticals | N/A | |
| Steven Stein | Incyte | 51 | |
| Jayson Dallas | Ultragenyx | 49 | |
| Henry Fuchs | Biomarin Pharmaceutical | 60 | |
| Rebecca Taub | Madrigal Pharmaceuticals | 66 | |
| Martin Auster | Ascendis Pharma AS | 38 | |
| Manmeet Soni | Alnylam Pharmaceuticals | 40 | |
| Harry Leonhardt | Halozyme Therapeutics | 61 | |
| Masako Nakamura | Alnylam Pharmaceuticals | N/A | |
| Wenqing Yao | Incyte | 55 | |
| David Gryska | Incyte | 61 | |
| Catherine Kelleher | Viking Therapeutics | N/A | |
| Yvonne Greenstreet | Alnylam Pharmaceuticals | 55 | |
| Rafael MD | Zai Lab | 60 | |
| Thomas Lackner | Apellis Pharmaceuticals | 51 | |
| Jeffrey Hessekiel | Exelixis | 49 | |
| Dashyant Dhanak | Incyte | 63 | |
| Amy Broidrick | Viking Therapeutics | N/A | |
| David Zaccardelli | United Therapeutics | 50 | |
Management Performance
| Return On Equity | -0.28 | |||
| Return On Asset | -0.13 |
Seagen Inc Leadership Team
Elected by the shareholders, the Seagen's board of directors comprises two types of representatives: Seagen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Seagen. The board's role is to monitor Seagen's management team and ensure that shareholders' interests are well served. Seagen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Seagen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roger Dansey, Chief Medical Officer | ||
| Vaughn Himes, Executive VP of Process Sciences and Technical Operations | ||
| Daniel Welch, Independent Director | ||
| Felix Baker, Lead Independent Director | ||
| Nancy Simonian, Independent Director | ||
| Peggy Pinkston, IR Contact Officer | ||
| Charles Romp, Ex US | ||
| MS JD, Chief Officer | ||
| Darren Cline, Executive Vice President - Commercial | ||
| Eric Dobmeier, COO, Corporate Secretary | ||
| Todd Simpson, CFO and Principal Accounting Officer | ||
| Pinkston Peggy, Senior Director - Corporate Communications | ||
| David Gryska, Independent Director | ||
| David Caouette, VP Communications | ||
| Srinivas Akkaraju, Independent Director | ||
| Alpna Seth, Director | ||
| Matt Skelton, VP Marketing | ||
| Marc Lippman, Independent Director | ||
| Jonathan Drachman, Chief Medical Officer and Executive Vice President Research and Development | ||
| Jean Liu, Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary | ||
| Robert Lechleider, Senior Vice President - Clinical Development | ||
| Christopher Pawlowicz, Ex HR | ||
| Clay Siegall, Co-Founder, Chairman, CEO and Pres | ||
| Robin Taylor, Chief Commercial Officer | ||
| Dennis Benjamin, Senior Vice President - Translational Research | ||
| Roger MD, Pres RD | ||
| John Orwin, Director | ||
| John McLaughlin, Independent Director |
Seagen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Seagen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.28 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.33) % | |||
| Operating Margin | (0.35) % | |||
| Current Valuation | 42.06 B | |||
| Shares Outstanding | 188.66 M | |||
| Shares Owned By Insiders | 0.81 % | |||
| Shares Owned By Institutions | 88.82 % | |||
| Number Of Shares Shorted | 9.58 M | |||
| Price To Earning | 32.75 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the Seagen Inc information on this page should be used as a complementary analysis to other Seagen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Seagen Stock
If you are still planning to invest in Seagen Inc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Seagen's history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |